From DCAT Value Chain Insights (VCI)
The European Medicines Agency (EMA) will launch a final round of targeted consultations with key stakeholders on its draft policy on publication of and access to clinical-trial data at the beginning of May. This will give key stakeholders and the agency the opportunity to address any outstanding issues before the final policy is presented to the EMA's Management Board for endorsement in June 2014.
The agency will liaise shortly with organisations representing patients, academia, pharmaceutical industry, as well as European Union (EU) institutions.
EMA said in a statement it "is committed to pursuing the objective of full transparency regarding clinical trial data because it believes that the release of data contributes to establishing trust and confidence in the system." The clinical trial data policy runs in parallel to other initiatives in the EU to increase transparency of clinical trials, most notably the new Clinical Trials Regulation which received a favorable vote in the European Parliament on April 2, 2014. This piece of legislation is expected to come into force in mid-2016.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription